Could a second dose of dengue vaccine boost protection for kids?
NCT ID NCT07712926
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether a two-dose regimen of the Butantan-DV dengue vaccine, given nine months apart, produces a stronger immune response than a single dose in children and adolescents aged 2 to 17 who have never had dengue. The trial also checks that the vaccine made at a new manufacturing facility works as well as the original. Participants receive either two doses of the vaccine, one vaccine and one placebo, or the vaccine from the new facility, and researchers measure antibody levels and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a live attenuated dengue vaccine called Butantan-DV
- What this could lead to
- If successful, this could lead to a more effective two-dose dengue vaccine schedule for children and adolescents, potentially reducing severe dengue cases.
- What could go wrong
- This is an early-stage Phase 3b trial focused on immune response, not yet on preventing actual disease. The vaccine may not provide strong protection against all four dengue types, and safety in young children is still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE FEVER WITH WARNING SIGNS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.